利波卡林-2通过激活JAK2/STAT3信号通路来促进NSCLC的进展
Jinjin Zhang1, Qin Xu1, Gengyun Sun2
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Province, 230022, Hefei, China.
利波卡林-2 (LCN2) 在非小细胞肺癌 (NSCLC) 中被上调,通过激活JAK2/STAT3通路来促进瘤生长和转移. 准LCN2为NSCLC患者提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 利波卡林-2 (LCN2) 涉及瘤发生,但其在NSCLC中的作用尚不清楚.
- 这项研究研究了LCN2在NSCLC中的功能,重点关注JAK2/STAT3通路.
研究的目的:
- 阐明Lipocalin-2 (LCN2) 在非小细胞肺癌 (NSCLC) 中的作用.
- 研究Janus酶2/信号转换器和转录3激活器 (JAK2/STAT3) 信号通路在LCN2-介导NSCLC进展中的参与.
主要方法:
- 使用TCGA,GEO,UALCAN和UCSC-XENA对NSCLC中LCN2表达的生物信息分析.
- 在体外测试 (CCK-8,EDU,伤口愈合,transwell) 和体内异种移植模型来评估LCN2的功能影响.
- 西方涂抹和药理抑制 (AG490) 检查JAK2/STAT3通路激活.
主要成果:
- 在NSCLC组织和细胞系中,LCN2显著上调,与预后不佳相关.
- LCN2的淘汰抑制了NSCLC细胞的增殖,迁移和入侵,同时促进了细胞亡.
- LCN2激活了JAK2/STAT3通路,阻断该通路可以逆转LCN2的致癌作用.
结论:
- 通过激活JAK2/STAT3信号通路,LCN2在NSCLC中起到瘤基因的作用.
- 准LCN2或其下游效应器为NSCLC提供了潜在的治疗途径.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway
